Clinical outcomes of ceftolozane-tazobactam dosing in patients with sepsis undergoing renal replacement therapies
CONCLUSION: The used doses of C/T in this study were higher than those approved by the U.S. FDA, while clinical success is uncertain. Larger outcomes and pharmacokinetics studies are needed to establish effective dosing and therapy duration.PMID:37439527 | DOI:10.5414/CN111166 (Source: Clinical Nephrology)
Source: Clinical Nephrology - July 13, 2023 Category: Urology & Nephrology Authors: Wasim S El Nekidy Mooza Al Ali Emna Abidi Islam M Ghazi Nizar Attallah Rania El Lababidi Fadi Hijazi Jihad Mallat Source Type: research
Clinical outcomes of ceftolozane-tazobactam dosing in patients with sepsis undergoing renal replacement therapies
CONCLUSION: The used doses of C/T in this study were higher than those approved by the U.S. FDA, while clinical success is uncertain. Larger outcomes and pharmacokinetics studies are needed to establish effective dosing and therapy duration.PMID:37439527 | DOI:10.5414/CN111166 (Source: Clinical Nephrology)
Source: Clinical Nephrology - July 13, 2023 Category: Urology & Nephrology Authors: Wasim S El Nekidy Mooza Al Ali Emna Abidi Islam M Ghazi Nizar Attallah Rania El Lababidi Fadi Hijazi Jihad Mallat Source Type: research
Clinical outcomes of ceftolozane-tazobactam dosing in patients with sepsis undergoing renal replacement therapies
CONCLUSION: The used doses of C/T in this study were higher than those approved by the U.S. FDA, while clinical success is uncertain. Larger outcomes and pharmacokinetics studies are needed to establish effective dosing and therapy duration.PMID:37439527 | DOI:10.5414/CN111166 (Source: Clinical Nephrology)
Source: Clinical Nephrology - July 13, 2023 Category: Urology & Nephrology Authors: Wasim S El Nekidy Mooza Al Ali Emna Abidi Islam M Ghazi Nizar Attallah Rania El Lababidi Fadi Hijazi Jihad Mallat Source Type: research
Clinical outcomes of ceftolozane-tazobactam dosing in patients with sepsis undergoing renal replacement therapies
CONCLUSION: The used doses of C/T in this study were higher than those approved by the U.S. FDA, while clinical success is uncertain. Larger outcomes and pharmacokinetics studies are needed to establish effective dosing and therapy duration.PMID:37439527 | DOI:10.5414/CN111166 (Source: Clinical Nephrology)
Source: Clinical Nephrology - July 13, 2023 Category: Urology & Nephrology Authors: Wasim S El Nekidy Mooza Al Ali Emna Abidi Islam M Ghazi Nizar Attallah Rania El Lababidi Fadi Hijazi Jihad Mallat Source Type: research
Clinical outcomes of ceftolozane-tazobactam dosing in patients with sepsis undergoing renal replacement therapies
CONCLUSION: The used doses of C/T in this study were higher than those approved by the U.S. FDA, while clinical success is uncertain. Larger outcomes and pharmacokinetics studies are needed to establish effective dosing and therapy duration.PMID:37439527 | DOI:10.5414/CN111166 (Source: Clinical Nephrology)
Source: Clinical Nephrology - July 13, 2023 Category: Urology & Nephrology Authors: Wasim S El Nekidy Mooza Al Ali Emna Abidi Islam M Ghazi Nizar Attallah Rania El Lababidi Fadi Hijazi Jihad Mallat Source Type: research
Clinical outcomes of ceftolozane-tazobactam dosing in patients with sepsis undergoing renal replacement therapies
CONCLUSION: The used doses of C/T in this study were higher than those approved by the U.S. FDA, while clinical success is uncertain. Larger outcomes and pharmacokinetics studies are needed to establish effective dosing and therapy duration.PMID:37439527 | DOI:10.5414/CN111166 (Source: Clinical Nephrology)
Source: Clinical Nephrology - July 13, 2023 Category: Urology & Nephrology Authors: Wasim S El Nekidy Mooza Al Ali Emna Abidi Islam M Ghazi Nizar Attallah Rania El Lababidi Fadi Hijazi Jihad Mallat Source Type: research
Clinical outcomes of ceftolozane-tazobactam dosing in patients with sepsis undergoing renal replacement therapies
CONCLUSION: The used doses of C/T in this study were higher than those approved by the U.S. FDA, while clinical success is uncertain. Larger outcomes and pharmacokinetics studies are needed to establish effective dosing and therapy duration.PMID:37439527 | DOI:10.5414/CN111166 (Source: Clinical Nephrology)
Source: Clinical Nephrology - July 13, 2023 Category: Urology & Nephrology Authors: Wasim S El Nekidy Mooza Al Ali Emna Abidi Islam M Ghazi Nizar Attallah Rania El Lababidi Fadi Hijazi Jihad Mallat Source Type: research
Case report: Rehabilitation course in thrombocytopenia, anasarca, fever, reticulin fibrosis/renal failure, and organomegaly syndrome complicated by cerebral infarction in the left parabolic coronary region
Although thrombocytopenia, anasarca, fever, reticulin fibrosis/renal failure, and organomegaly (TAFRO) syndrome was first reported in 2010, its pathogenesis and prognosis are still unknown. Moreover, reports on rehabilitation in patients with TAFRO are limited. In severe cases, dyspnea and muscle weakness could impede improvements in activities of daily living (ADL). However, reports on exercise intensity showed no worsening of TAFRO within the load of 11–13 on the Borg scale. Herein, we describe the rehabilitation and progress in a 61-year-old woman with TAFRO syndrome complicated by cerebral infarction from early onset...
Source: Frontiers in Neurology - July 13, 2023 Category: Neurology Source Type: research
Effects of high-flux hemodialysis and hemodiafiltration on the mortality of patients with end-stage kidney disease: a meta-analysis
CONCLUSIONS: Compared with HDF, HFHD has no obvious benefits for all-cause mortality or cardiovascular mortality in patients with ESKD, but reduced risk of infection-related death.PMID:37427760 | DOI:10.1080/0886022X.2022.2147436 (Source: Renal Failure)
Source: Renal Failure - July 10, 2023 Category: Urology & Nephrology Authors: Sihui Ma Nan Pu Juan Ma Source Type: research
Effects of high-flux hemodialysis and hemodiafiltration on the mortality of patients with end-stage kidney disease: a meta-analysis
CONCLUSIONS: Compared with HDF, HFHD has no obvious benefits for all-cause mortality or cardiovascular mortality in patients with ESKD, but reduced risk of infection-related death.PMID:37427760 | PMC:PMC10334859 | DOI:10.1080/0886022X.2022.2147436 (Source: Renal Failure)
Source: Renal Failure - July 10, 2023 Category: Urology & Nephrology Authors: Sihui Ma Nan Pu Juan Ma Source Type: research
A 15-Year Retrospective Study of Supportive Extracorporeal Therapies Including Plasma Exchange and Continuous Venovenous Hemodiafiltration of 114 Adults with Acute Liver Failure Awaiting Liver Transplantation
CONCLUSIONS This combined extracorporeal therapy can be used as a supportive treatment for both recovery and bridge to liver transplantation in patients with acute liver failure. In addition, treatment can be continued until liver regeneration and until a usable donor is found.PMID:37365780 | DOI:10.12659/AOT.939745 (Source: Annals of Transplantation)
Source: Annals of Transplantation - June 27, 2023 Category: Transplant Surgery Authors: Ilhan Ocak Source Type: research
A 15-Year Retrospective Study of Supportive Extracorporeal Therapies Including Plasma Exchange and Continuous Venovenous Hemodiafiltration of 114 Adults with Acute Liver Failure Awaiting Liver Transplantation
CONCLUSIONS This combined extracorporeal therapy can be used as a supportive treatment for both recovery and bridge to liver transplantation in patients with acute liver failure. In addition, treatment can be continued until liver regeneration and until a usable donor is found.PMID:37365780 | DOI:10.12659/AOT.939745 (Source: Annals of Transplantation)
Source: Annals of Transplantation - June 27, 2023 Category: Transplant Surgery Authors: Ilhan Ocak Source Type: research
A 15-Year Retrospective Study of Supportive Extracorporeal Therapies Including Plasma Exchange and Continuous Venovenous Hemodiafiltration of 114 Adults with Acute Liver Failure Awaiting Liver Transplantation
CONCLUSIONS This combined extracorporeal therapy can be used as a supportive treatment for both recovery and bridge to liver transplantation in patients with acute liver failure. In addition, treatment can be continued until liver regeneration and until a usable donor is found.PMID:37365780 | DOI:10.12659/AOT.939745 (Source: Annals of Transplantation)
Source: Annals of Transplantation - June 27, 2023 Category: Transplant Surgery Authors: Ilhan Ocak Source Type: research
A 15-Year Retrospective Study of Supportive Extracorporeal Therapies Including Plasma Exchange and Continuous Venovenous Hemodiafiltration of 114 Adults with Acute Liver Failure Awaiting Liver Transplantation
CONCLUSIONS This combined extracorporeal therapy can be used as a supportive treatment for both recovery and bridge to liver transplantation in patients with acute liver failure. In addition, treatment can be continued until liver regeneration and until a usable donor is found.PMID:37365780 | DOI:10.12659/AOT.939745 (Source: Annals of Transplantation)
Source: Annals of Transplantation - June 27, 2023 Category: Transplant Surgery Authors: Ilhan Ocak Source Type: research
